Explore the questions shaping modern bioprocessing
BioProcess360 convenes scientists, downstream teams, and technical leaders around the application-specific questions shaping AAV, lentiviral, mAb, and emerging biologics’ purification workflows.
From theoretical exploration through to technical validation, NAVIGATE helps guide how uncertainties can evolve toward clearer decisions and better process solutions.
Bioprocessing questions rarely arrive fully defined.
In one application, pressure shows up as fouling, variability, or loss of recovery. In another, it appears as upstream inconsistency, rising impurity complexity, analytical gaps, or uncertainty around whether a process will hold as scale increases.
NAVIGATE is built for that layer of technical uncertainty.
It brings application-specific discussion into clearer focus through expert conversation, structured peer exchange, and technical follow-up designed to surface where the process is straining, what acceptable performance looks like, and which questions deserve deeper validation.
Why Scientists Take Part
Broader context, closer to the process
NAVIGATE gives participants a stronger read on where peers are seeing the same bottlenecks, how those issues are being described, and which concerns are showing up often enough to matter.
Better visibility into what is still unsettled
Not every process question has a stable benchmark or shared industry view. NAVIGATE helps scientists see where assumptions are still moving.
Sharper language for internal discussion
Many bioprocessing challenges are easy to feel and harder to define. NAVIGATE helps clarify the language around failure modes, tradeoffs, thresholds, and workflow decisions.
A chance to shape the discussion early
The strongest technical conversations often begin before consensus forms. Participation helps bring real process experience into that discussion.
Focus Areas
AAV
Why do viral vector processes still struggle to scale reliably?
AAV discussions within NAVIGATE focus on the technical pressure points that emerge as programs move from early clinical development toward late-stage and commercial manufacturing. These include upstream variability, transfection efficiency, plasmid quality, capsid titer, impurity burden, downstream variability, recovery, capsid integrity, and comparability expectations during scale-up.
The central question is not only where purification becomes difficult, but why variability accumulates across the process. How are teams managing upstream inputs that influence downstream performance? Which steps become less predictable at larger scale? How are process changes being evaluated across serotypes, batches, and manufacturing volumes? And where are teams making practical tradeoffs between recovery, robustness, analytical confidence, and commercial readiness?
NAVIGATE gives AAV teams a peer-led forum to compare these challenges against broader industry experience rather than evaluating them as isolated process issues.
Lentivirus
What kind of purification problem is really emerging here?
For lentivirus, the emphasis is earlier and more directional.
NAVIGATE is following questions around in vivo momentum, purity and scalability expectations, infectivity preservation, impurity profiles, and the logic behind membrane, resin, or hybrid approaches.
That makes the value of participation different here. It is less about confirming a settled problem and more about helping define what the problem actually is.
mAbs
How much strain is the platform already carrying?
mAb discussions within NAVIGATE focus on the growing pressure being placed on established manufacturing platforms as titers rise, molecule formats become more complex, and expectations for robustness, scalability, cost, and product quality continue to increase.
The classic mAb platform remains a powerful foundation, but the demands placed on it are changing. Higher titers can shift impurity burden and downstream load. More complex molecules can introduce challenges around aggregation, variants, clearance, and manufacturability. At the same time, teams are expected to move faster, scale reliably, and maintain regulatory confidence with fewer surprises.
NAVIGATE gives mAb teams a place to discuss where platform approaches are still holding, where they are starting to show strain, and how scientists are adapting process strategies to meet the next generation of manufacturing expectations.
Other
Where important purification questions are still taking shape
Not every meaningful purification discussion arrives with a clean modality label.
NAVIGATE also leaves room for emerging advanced therapeutics applications, adjacent purification challenges, and hybrid workflows where the category language is still catching up to the technical reality.
In those areas, the goal is not to generalize too early. It is to bring the right question into focus, understand whether it is broadly shared, and build discussion around the application itself.
How NAVIGATE Takes Shape
• Podcasts and expert conversations surface recurring friction points and the language scientists are using to describe them.
• Roundtables test whether a concern is widely shared, application-specific, or still too early to define cleanly.
• Webinars and surveys help sharpen thresholds, benchmark expectations, and workflow tradeoffs.
• Technical follow-up carries the strongest questions into deeper discussion with more application context.
That staged structure allows NAVIGATE to move from early problem recognition toward clearer technical definition and, where warranted, more formal proof.
Who NAVIGATE is Built For
NAVIGATE is intended for people working close to purification decisions:
Process development scientists
Downstream purification specialists
Technical leaders evaluating workflow changes
Teams assessing new technologies, workflow changes, and platform evolution across modalities
If your work lives near the point where process behavior, benchmark uncertainty, and technical judgment meet, NAVIGATE is designed to be useful there.
Better purification decisions begin with a clearer read on the question.
NAVIGATE brings application-specific discussion into focus across AAV, lentivirus, mAbs, and emerging advanced therapeutics workflows, giving scientists a stronger view of where the field is aligned, where it is divided, and where the next important questions are coming into view.